Immunome, Inc. Common Stock IMNM
i
Market datapartial · fetched 2026-11-11T14:53:25.914Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T14:53:12.116147036Z
FundamentalsAlpha Vantage · unavailable
Immunome, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 16.73 | 164.9% | 17.5% | |||
| 30Δ | 17.27 | 182.2% | 16.6% | |||
| 35Δ | 17.82 | 199.5% | 15.8% | |||
| 40Δ | 28.74 | 407.7% | 63.8% | 18.53 | 206.2% | 14.3% |
| 45Δ | 24.78 | 340.0% | 43.2% | |||
| 50Δ | 19.78 | 172.0% | 13.2% | |||
| 55Δ | 19.21 | 192.6% | 12.7% | 20.03 | 132.6% | 6.2% |
| 60Δ | 18.53 | 190.2% | 10.6% | 20.38 | 123.0% | 5.1% |
| 65Δ | 20.73 | 113.4% | 3.9% | |||
| 70Δ | 21.09 | 104.9% | 2.8% | |||
| 75Δ | 21.51 | 100.6% | 2.1% | |||
| 80Δ | 16.88 | 102.0% | 2.1% | 21.92 | 96.3% | 1.5% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 16.73
- IV
- 164.9%
- B/E move
- 17.5%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 17.27
- IV
- 182.2%
- B/E move
- 16.6%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 17.82
- IV
- 199.5%
- B/E move
- 15.8%
40Δ
- Pseudo strike
- 28.74
- IV
- 407.7%
- B/E move
- 63.8%
- Pseudo strike
- 18.53
- IV
- 206.2%
- B/E move
- 14.3%
45Δ
- Pseudo strike
- 24.78
- IV
- 340.0%
- B/E move
- 43.2%
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 19.78
- IV
- 172.0%
- B/E move
- 13.2%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 19.21
- IV
- 192.6%
- B/E move
- 12.7%
- Pseudo strike
- 20.03
- IV
- 132.6%
- B/E move
- 6.2%
60Δ
- Pseudo strike
- 18.53
- IV
- 190.2%
- B/E move
- 10.6%
- Pseudo strike
- 20.38
- IV
- 123.0%
- B/E move
- 5.1%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 20.73
- IV
- 113.4%
- B/E move
- 3.9%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 21.09
- IV
- 104.9%
- B/E move
- 2.8%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 21.51
- IV
- 100.6%
- B/E move
- 2.1%
80Δ
- Pseudo strike
- 16.88
- IV
- 102.0%
- B/E move
- 2.1%
- Pseudo strike
- 21.92
- IV
- 96.3%
- B/E move
- 1.5%
Options history
Table
| Date | IV (%) |
|---|---|
| 102.44% | |
| 88.48% | |
| 99.05% | |
| 95.86% | |
| 101.07% | |
| 96.76% | |
| 97.94% | |
| 94.49% | |
| 104.45% | |
| 100.07% |
Biotechnology
IMRX
Immuneering Corp (IMRX) is a cutting-edge biotechnology firm dedicated to advancing targeted therapeutics for cancer and other critical illnesses through its proprietary drug…
More →IMTX
Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies for the treatment of cancer in…
More →IMUX
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune and inflammatory…
More →IMVT
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company is headquartered in New York,…
More →INBX
Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. The company is headquartered in La Jolla,…
More →INCY
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
More →